ORIC Q3'26 Results Due November 9; Revenue Estimate Is Zero
Oric Pharmaceuticals is scheduled to report Q3 results on November 9. Revenue is estimated at zero, with EPS anticipated at a loss; the release time is not specified.
Related stories
Fox Reports Higher Q1 FY27 EPS and Revenue
Fox reported year-over-year increases in Q1 FY27 earnings per share and revenue.
M impact | EQUITY | Nov 02, 2026, 01:47 PM UTC
IDEXX Executive Says Covet Revenue Run Rate Is About $20 Million
An IDEXX executive said Covet revenue is growing at strong double-digit rates.
M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC
Infineon and Qualcomm Technologies Sign Automated Driving Agreement
M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC
Fox Shares Rise After Q1 Results Top Estimates
Fox shares rise after first-quarter results top estimates, supported by advertising.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC
AAR Proposes $955 Million and $960 Million Senior Note Offerings
AAR proposed $955 million of senior notes due 2031 and $960 million of senior notes due 2034.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC
Teva shares fall after rare brain disorder drug trial halted
US-listed shares of Israel-based Teva fell after a trial of a drug for a rare brain disorder was halted.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC